| INTRODUCTION
Familial hypercholesterolemia (FH) is a genetic cause of premature myocardial infarction (PMI) due to lifelong elevated serum low-density lipoprotein cholesterol (LDL-C) levels. 1 As an autosomal genetic disease, low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), proprotein convertase subtilisin-kexin type 9 (PCSK9) and low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) genes are the most important pathogenic genes of FH. 2, 3 Mutations of LDLR, PCSK9 and APOB genes are autosomal dominant inheritance.
However, LDLRAP1 gene mutations produce a very rare recessive disease known as autosomal recessive hypercholesterolemia (ARH) with a similar phenotype. 4 It is generally believed that the prevalence of heterozygous FH is 1/500 and that of homozygous FH is 1/1000000 among the population. 5 In special subgroups of the population, such as PMI, the
We certify that the manuscript is original and that no portion (including figures or tables) is under consideration elsewhere or has been previously published in any form other than as an abstract. I have read the manuscript and approved its submission to Clinical Cardiology.
prevalence of FH is often higher. It has been shown that early diagnosis of FH is critical for prognosis, and the efficiency in the diagnosis of FH has been improved as the recent technical progress in genetic testing. 6 However, in clinical practice, early diagnosis is still difficult for many cases with FH. Due to the difference in the prevalence of FH among countries and ethnicities, and complexities in the genetic variants, 7 there are some limitations in the current diagnostic criteria and no criteria are universally applied. 8 In China, there are few studies analyzing FH patients using genetic analysis, and novel genetic variants identified remain scarce. 9 The rate of timely diagnosis and treatment of FH is far from satisfaction. As PMI represents a critical clinical manifestation of patients with FH, the aim of this study was to investigate the prevalence of FH using genetic testing in a cohort of Chinese patients with PMI, and to evaluate different diagnostic criteria. 
| METHODS

| Subjects
| Collection of clinical and laboratory data
The clinical data, including age, sex, body mass index, and family history of premature coronary heart disease (pCHD), were collected.
Results of laboratory examinations such as routine blood test and biochemical test during the first 24 hours after admission were also obtained. The severity of CHD was assessed according to Gensini score system as described in the previous study. 11 Routine blood test was performed using the XN9000 automatic blood cell analyzer (Sysmex, Kobe, Japan). Biochemical testing was performed using the 5832 biochemical analyzer (Beckman, Atlanta, GA). Family history of pCHD was defined as pCHD in males aged <55 years old or females aged <60 years old in the first-degree relatives.
| Diagnostic criteria for FH
FH was diagnosed using the Dutch Lipid Clinic Network (DLCN) criteria which covered personal and family history of premature atherosclerosis, physical examination and LDL-C levels. 12 China's modified DLCN criteria proposed for FH diagnosis of the Chinese population were also employed. 13 Untreated LDL-C levels of individuals who were on lipid-lowering medications but had no pretreatment LDL-C data were conservatively adjusted by relative correction factors dependent on the dose and potency of statins. The correction factors were originated from the analysis of 71 original articles that were collated before establishing these criteria. 
| DNA extraction
Genomic DNA was extracted from blood cell samples using DNeasy
Blood Kit (Tianyihuyuan, Beijing, China), following the manufacturer's protocol.
| Mutation sequencing
The whole exon region of LDLR, PCSK9 and LDLRAP1 genes and the region at exon 26 of APOB gene (from 100bp to 200bp of p.
Arg3500), which were located at the LDLR-binding site, 5 were sequenced by Sanger sequencing, with the ABI 3730-XL Genetic Analyzer employed (ABI, Foster City, California).
| Sequence analysis and bioinformatic prediction of mutations
The LOVD database (http://www.LOVD.nl/LDLR), NCBI-ClinVar database (https://www.ncbi.nlm.nih.gov/pmc/), and the NCBIPubmed literature database (https://www.ncbi.nlm.nih.gov/pmc/)
were used to determine whether the mutations were "pathogenic" or "potentially pathogenic." If the mutation was not found in these databases, the Polyphen-2 software (Harvard, Boston, MA) was used to analyze conservation of the amino acid caused by the mutation; if the mutation was highly conserved among different species, it was defined as pathogenic mutation.
| Statistical analysis
The SPSS19.0 software (SPSS, Chicago, IL) was used for analysis.
Measurement data of normal distribution were represented as mean ± SD and examined using independent samples t test. Count data were examined using X 2 test. P < 0.05 indicated significant difference.
3 | RESULTS
| Clinical characteristics and pathogenic mutations of FH
A total of 225 patients who met the inclusion criteria were enrolled in the study, including 188 males (83.6%), and 37 females (16.4%), and the average age at the first onset of MI was 46.64 ± 7.21 years old.
Ten pathogenic mutations of LDLR, APOB, PCSK9 and LDLRAP1 genes were found in 11 of 225 patients, all of which were heterozygous. Among these 11 patients, there were 8 with LDLR mutation alone, 1 with APOB mutation alone, 1 with LDLRAP1 mutation alone and 1 with both LDLR (c.129G>C) and LDLRAP1 mutations (LDLRAP1 c.274G>A), without PCSK9 functional mutation. Among all mutations, 6 out of 10 mutations were classified to known "pathogenic" mutations, and other 4 mutations were classified to putative "likely pathogenic" mutations, which were newly discovered (Table 1) .
Because LDLRAP1 mutations cause ARH, 10 patients were diagnosed as FH by genetic testing, including 8 patients with LDLR mutation, 1 with APOB mutation and 1 with LDLR and LDLRAP1
mutations. The prevalence of FH diagnosed by genetic testing was 4.4%. Compared to mutation-negative patients, mutation-positive patients had more severe coronary lesions, and higher LDL-C levels ( Table 2 ).
| Clinical characteristics of patients with different gene mutations
Although FH cases with gene mutations generally had increased levels of LDL-C, LDL-C levels of individual cases with identified FH mutations were widely diverse. Only 6 out of 10 mutation-positive patients had LDL-C levels above 4.9 mmol/L (190 ng/dL), and LDL-C levels were significantly higher in carriers of LDLR mutation than in those of APOB mutation (5.72 mmol/L vs 4.93 mmol/L) ( Figure 1A ).
Coronary angiography of 10 patients with mutation-positive FH showed that there were three lesions in 8 patients, double-vessel disease in 1, and a single lesion in 1. The median Gensini score of FH patients was 70, which was significantly higher than that of non-FH patients. It was found that the median Gensini score of patients with LDLR mutation was higher than that of those with APOB mutation (78 vs 57), suggesting the patients with LDLR mutation had more severe coronary artery lesions ( Figure 1B ).
| Prevalence of FH according to different diagnostic criteria
In our study, DLCN criteria and modified DLCN criteria were used for the diagnosis of FH among PMI patients, respectively, and it was found that there were 12 patients (5.3%) classified as definite or prob- Table 3 shows comparison of the predictive values of these two different diagnostic criteria. The diagnosis of FH based on DLCN criteria was found to have a low sensitivity, whereas that the sensitivity of diagnosis based on modified DLCN criteria was higher. On the contrary, the specificity of FH diagnosis based on DLCN criteria was high, while the diagnosis based on modified DLCN criteria had a low specificity.
| Treatment of FH patients
As shown in Table 4 , the LDL-C levels in PMI patients with FH (genetic testing) were far from goal attainment. Only one of FH patients had LDL-C < 2.5 mmol/L, and none of the FH patients had LDL-C < 1.8 mmol/L. In terms of statin use, nine patients with FH (90%) had moderate intensity medication, and only one patient with FH (10%) had high intensity medication.
| DISCUSSION
In our study, the diagnosis of FH in patients with PMI was investigated by sequencing LDLR, APOB, PCSK9 and LDLRAP1 genes. It was found that patients with PMI showed a relatively high prevalence of mutation-positive FH (4.4%). Compared to mutation-negative patients, mutation-positive patients had more severe coronary lesions and higher LDL-C levels. LDLR mutation carriers had more severe coronary lesions than other mutation-positive patients. Moreover, the sensitivity of modified DLCN criteria was superior to DLCN criteria.
Although the prevalence of heterozygous FH (HeFH) was estimated to be 1:500, the recent data suggested a higher prevalence, highlighting that the burden of the disease is increasing. 15, 16 PMI is a great life-threatening disease, which is considered as one of the FIGURE 1 LDL-C levels (A) and Gensini scores (B) of patients with different gene mutations. The abscissa for peer review represents different genotypes, and the ordinate represents LDL-C levels (A) and Gensini scores (B) (n = 10). APOB, apolipoprotein B; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor
There was no significant difference in family history of pCHD between mutation-positive and mutation-negative patients, and only 20% mutation-positive FH patients had family history of pCHD, with reduced penetrance. 22 Their affected relatives received lipid-lowering therapy, and the self-reported family history may be unreliable. 23 The DLCN criteria are often used for the diagnosis of FH. Li et al 24 FH patients with different genotypes showed diverse LDL-C levels. Not all mutation-positive patients had LDL-C levels above a certain value. Khera et al 22 reported that 55% of the FH patients with pathogenic variants had LDL-C levels <190 mg/dL and 27% had LDL-C levels <130 mg/dL. Abul-Husn et al 27 found that LDL-C levels >190 mg/dL were present in 45% of the patients with FH variants. In our study, 60% of mutation-positive patients had LDL-C levels above 190 ng/dL. For patients with HeFH, it was found that LDL-C levels were higher in carriers of LDLR variants compared to APOB or PCSK9 variants, 27 consistent with our study. As shown in Figure 1 There were several limitations in our study. First, only the patients in a single center were enrolled, and the sample size was small, which may not reflect the general PMI population. Second, the new mutations we found should be verified by pedigrees or functional test.
Finally, the estimated LDL-C levels rather than the true untreated LDL-C levels were used for the medication treated patients, which might lead to bias. In conclusion, FH was found to be relatively common among PMI patients in China. Underdiagnosis and undertreatment of FH remain a big problem, which should arouse a widespread concern. 
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